We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Clinigen Group plc (CLIN) Ordinary 0.1p

Sell:586.00p Buy:587.50p 0 Change: 1.50p (0.26%)
FTSE AIM 100:1.48%
Market closed Prices as at close on 26 November 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:586.00p
Buy:587.50p
Change: 1.50p (0.26%)
Market closed Prices as at close on 26 November 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:586.00p
Buy:587.50p
Change: 1.50p (0.26%)
Market closed Prices as at close on 26 November 2021 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company's principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.

Contact details

Address:
Pitcairn House
Crown Square, First Avenue
BURTON UPON TRENT
DE14 2WW
United Kingdom
Telephone:
+44 (01283) 495010
Website:
https://www.clinigengroup.com/

Important dates

Future events
Final dividend payment date 04 January 2022 04/01/22
Final ex-dividend date 02 December 2021 02/12/21
Past events
AGM 24 November 2021 24/11/21
Final results 16 September 2021 16/09/21
Trading Announcement 13 July 2021 13/07/21
Trading Announcement 09 June 2021 09/06/21
Interim dividend payment date 13 April 2021 13/04/21
Interim ex-dividend date 18 March 2021 18/03/21
Interim results 23 February 2021 23/02/21
Trading Announcement 14 January 2021 14/01/21
Final dividend payment date 02 December 2020 02/12/20

General stock information

EPIC:
CLIN
ISIN:
GB00B89J2419
Market cap:
£782.20 million
Shares in issue:
133.37 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE AIM 100,FTSE AIM All Share

Key personnel

  • Shaun Chilton
    Chief Executive Officer, Director
  • Richard Paling
    Interim Chief Financial Officer, Group Financial Controller
  • Sam Herbert
    Chief Operating Officer
  • Amanda Miller
    General Counsel, Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.